Merck: positive data for molnupiravir

(CercleFinance.com) - Merck and Ridgeback Biotherapeutics have provided an update on the MOVE-OUT study of molnupiravir, their investigational oral antiviral drug for Covid-19, supporting an overall favorable benefit/risk assessment.


In this study population, molnupiravir reduced the risk of hospitalization or death from 9.7% in the placebo group (68/699) to 6.8% (48/709) in the molnupiravir group, for an absolute risk reduction of 3.0%.

Nine deaths were reported in the placebo group and one in the molnupiravir group. The adverse event profile of molnupiravir remained consistent with the profile presented in the planned interim analysis.


Copyright (c) 2021 CercleFinance.com. All rights reserved.